In a 64-year-old patient with rheumatoid arthritis receiving tofacitinib, do the progressive increases in mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) along with decreases in mean corpuscular hemoglobin concentration (MCHC), hemoglobin, white blood cell (WBC) count, and platelet count over seven years raise concern for myelodysplastic syndrome?

Progressive Cytopenias in RA Patient on Tofacitinib: MDS Evaluation Needed

These progressive hematologic changes over seven years—particularly the combination of macrocytosis (MCV 90→101), declining hemoglobin (17.8→16.1 g/dL), leukopenia (7000→4000), and thrombocytopenia (150,000→100,000)—warrant evaluation for myelodysplastic syndrome (MDS), though tofacitinib-related cytopenias must also be considered.

Key Diagnostic Considerations

MDS Diagnostic Thresholds

According to ESMO guidelines, MDS typically presents with:

• Hemoglobin <10 g/dL
• Platelet count <100,000/μL
• Absolute neutrophil count <1800/μL 1

Your patient's current values (hemoglobin 16.1 g/dL, platelets 100,000/μL) are at or near these thresholds, making this a critical juncture for evaluation.

The Macrocytosis Pattern Is Concerning

The progressive increase in MCV from 90 to 101 fL is particularly noteworthy as macrocytosis is a common finding in MDS 1. The accompanying increase in MCH (33→35) and decrease in MCHC (36→34.7) further support a macrocytic process. While these changes alone don't confirm MDS, they represent a red flag requiring investigation.

Tofacitinib's Hematologic Effects

The FDA label for tofacitinib notes that neutrophil counts decrease with treatment, and hemoglobin levels actually tend to increase 2. Recent real-world data confirm that all JAK inhibitors reduce absolute neutrophil counts, though baricitinib specifically increases platelet counts 3. Your patient's pattern—declining platelets, WBC, and hemoglobin—is not the typical tofacitinib profile, which makes drug effect alone an insufficient explanation.

Immediate Diagnostic Workup Required

Essential Studies

1. Peripheral blood smear examination - Look for dysplastic features, blasts, and confirm macrocytosis
2. Bone marrow aspiration and biopsy - Required for definitive MDS diagnosis if peripheral findings are suggestive 1
3. Cytogenetic analysis - IPSS-R scoring requires karyotype for risk stratification 1
4. Molecular testing - SF3B1, TP53, and other mutations provide prognostic information 1

Additional Laboratory Assessment

• Vitamin B12 and folate levels (exclude nutritional macrocytosis)
• Reticulocyte count (assess bone marrow response)
• LDH and haptoglobin (exclude hemolysis)
• Peripheral blood blast percentage on two separate occasions 1

Clinical Decision Algorithm

If peripheral smear shows dysplasia or blasts:

• Proceed directly to bone marrow evaluation
• Do not attribute findings solely to tofacitinib

If peripheral smear is unremarkable but cytopenias persist:

• Consider 4-6 week tofacitinib holiday to assess drug contribution
• Monitor complete blood counts weekly during this period
• If counts fail to improve or worsen, proceed to bone marrow evaluation

If counts improve significantly off tofacitinib:

• Drug-related cytopenia more likely
• Consider alternative RA therapy
• Continue monitoring as MDS can still develop independently

Critical Pitfalls to Avoid

Don't Delay Based on "Mild" Cytopenias

While your patient's hemoglobin (16.1 g/dL) seems reassuring, the trajectory matters more than absolute values. The seven-year progressive decline across multiple cell lines suggests a bone marrow process rather than isolated drug effect.

Don't Assume RA-Related Anemia

RA typically causes normocytic or microcytic anemia of chronic disease, not macrocytosis 4. The MCV increase argues against RA as the primary explanation.

Consider the RA-MDS Association

While uncommon, MDS has been reported in RA patients, sometimes related to prior DMARD exposure 5. Your patient's age (64 years) also places them in the typical MDS demographic.

Management Implications

If MDS Is Confirmed

• Lower-risk MDS (IPSS-R score ≤3): Supportive care, erythropoiesis-stimulating agents if appropriate, consider iron chelation if transfusion-dependent 1
• Higher-risk MDS (IPSS-R score >3): Hypomethylating agents (azacitidine), consider allogeneic stem cell transplant evaluation 1
• RA management becomes secondary but can continue with careful monitoring

Tofacitinib Continuation Decision

If MDS is excluded and cytopenias are tofacitinib-related:

• Dose reduction may be considered, though efficacy may be compromised
• Switch to alternative RA therapy (different JAK inhibitor or biologic DMARD)
• The EULAR guidelines note that JAK inhibitors require careful monitoring for cytopenias 6

The combination of progressive macrocytosis with multi-lineage cytopenias over seven years mandates hematologic evaluation regardless of tofacitinib use. Peripheral smear review and likely bone marrow examination are the next appropriate steps to definitively distinguish between drug effect, MDS, or other bone marrow pathology.